Released Aug 5, 2020, after the close
10-Q filed Aug 5, 2020, 36 days after period end · 0001564590-20-036806
Q2 2020 · 10-Q
Revenue$5.47M$5.47M +94.0% vs Q2 2019+117.3% vs Q1 2020
Net Income-$28.07M-$28.07M N/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.35-$0.35 N/M vs Q2 2019N/M vs Q1 2020
Operating Income-$28,707,000N/M
Operating Cash Flowderived$38,841,000N/M
Free Cash Flowderived$38,205,000N/M
Margins · derived
Operating margin-525.3%+329.7 pt vs Q2 2019
Net margin-513.7%+319.8 pt vs Q2 2019
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $5.47M | $2.82M | $1.03M | $1.03M |
| Net Income | -$28.07M | -$23.48M | -$19.65M | -$9.65M |
| EPS Diluted | -$0.35 | -$0.36 | -$0.37 | -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR